Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...
Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback